Zybiraa 250 mg (Abiraterone Acetate Tablets) – Overview
Zybiraa 250 mg contains Abiraterone Acetate, an FDA-approved medication used in the treatment of metastatic castration-resistant prostate cancer (mCRPC). It works by inhibiting an enzyme called CYP17, which is essential for the production of androgens (male hormones). Lowering androgen levels helps slow the growth and spread of prostate cancer. Manufactured by BDR Pharmaceuticals, Zybiraa is widely prescribed alongside prednisone to improve survival rates and enhance the quality of life in patients with advanced prostate cancer.
Benefits of Zybiraa 250 mg (Abiraterone Acetate Tablets):
- Effective Cancer Treatment: Helps manage advanced-stage prostate cancer by reducing androgen production.
- Improves Survival Rates: Clinically proven to extend life expectancy in patients with mCRPC.
- Non-Chemotherapy Option: Unlike chemotherapy, Zybiraa is an oral therapy, making it a convenient treatment choice.
- Reduces Symptoms: Helps in pain relief, lowers PSA levels, and slows cancer progression.
- Manufactured by BDR Pharmaceuticals: Ensures high-quality production with strict safety and efficacy standards.
Specification/Additional Details:
- Strength: 250 mg
- Packaging Type: Bottle
- Packaging Size: 120 tablets per bottle
- Brand: Zybiraa
- Manufactured By: Zydus
- Country of Origin: India
For bulk orders, wholesale pricing, and inquiries, feel free to contact us!
Reviews
There are no reviews yet.